Joined Today: 3

KERX Keryx Biopharmaceuticals, Stock Message Board

All Messages

KERX Message Board Home | Join The KERX Group |

#10: Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
TheMachine	April 14, 2008 12:18:24 AM
Plan to Include Refocusing of Operations and Workforce Reduction NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today... view message ignore post recommend post

#9: Keryx Biopharmaceuticals to Present at JPMorgan Healthcare Conference
TheMachine	January 18, 2008 05:28:11 PM
NEW YORK, Jan. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief... view message ignore post recommend post

#8: Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
FastFun	December 16, 2007 06:50:50 PM
Dr. Paul Richardson presents Phase 1 results demonstrating clinical activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an... view message ignore post recommend post

#7: DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
FastFun	December 16, 2007 06:50:05 PM
'Room Temp' Technology Builds on Consumer Appeal and Tactical Importance of Needle-less Vaccinations IRVING, Texas, Dec. 10 /PRNewswire-FirstCall/ -- An experimental drug delivery... view message ignore post recommend post

#6: Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
FastFun	December 7, 2007 07:09:11 PM
Data on Perifosine in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma to be presented on Saturday, December 8th at 5:30pm NEW YORK, Dec. 7 /PRNewswire-FirstCall/ --... view message ignore post recommend post

#5: Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
FastFun	December 7, 2007 07:04:08 PM
No Safety Concerns Raised Sulodexide Phase 3 study to continue without modification NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced... view message ignore post recommend post

#4: Re: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
FastFun	November 30, 2007 11:41:49 AM
I wonder if this is "fast tracked" . I hope it passes the FDA ASAP view message view parent message ignore post recommend post

#3: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
FastFun	November 26, 2007 08:34:21 PM
Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1... view message ignore post recommend post

#2: Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
FastFun	October 15, 2007 11:54:18 PM
Deal Includes up to $100MM in License Fees and Potential Milestone Payments NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today... view message ignore post recommend post

#1: KERX, Keryx Biopharmaceuticals to Present at The Bank of America 2007 Health Care Conference
Jason	June 3, 2007 08:53:23 PM
Presentation Scheduled for Wednesday, May 30th at 11:20am PT Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX Stock Forums) today announced that Michael S. Weiss, the Company's Chairman and Chief... view message ignore post recommend post

Group Home | Login if you want to post a message